Abstract
Chronic lymphocytic leukemia (CLL) is a low-grade B-cell non-Hodgkin lymphoma. Skin involvement is observed in up to 25% of patients. A 70-year-old men with presented with prominent erythematous facial infiltrates. After the diagnosis of CLL was established, he showed a good hematologic response to the monoclonal antibody rituximab, but the skin infiltrates were therapy-resistant.
Publication types
-
Case Reports
-
Comparative Study
-
English Abstract
MeSH terms
-
Aged
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use
-
Drug Resistance*
-
Face / pathology
-
Humans
-
Interferon-alpha / administration & dosage
-
Interferon-alpha / therapeutic use
-
Leukemia, Lymphocytic, Chronic, B-Cell / classification
-
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
-
Leukemic Infiltration / drug therapy*
-
Leukemic Infiltration / pathology
-
Male
-
Rituximab
-
Skin / pathology*
-
Time Factors
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Interferon-alpha
-
Rituximab